

INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-01201	Serial No: 09/ 436,347
	Inventor(s): Christine WHITE <i>et al.</i>	Examiner: A.M. HARRIS
	Filed: 9 November 1999	Art Unit: 1643

U.S. PATENT DOCUMENTS

INITIAL	INDEX	DOCUMENT	DATE	NAME	CLASS	SUB.	FILING DATE
amb	D316	5,399,061 5,843,439	1 Dec 1998	Anderson	—	—	
amb	D317	2003/0147885	7 Aug 2003	Anderson	—	—	

OTHER DOCUMENTS

INITIAL	INDEX	CITATION
amb	D318	Byrd J.C. et al. <i>Blood</i> 92(10 Suppl. 1): 106a, abst. no. 433, Nov. 1998. Rituximab therapy in previously treated Waldenstrom's macroglobulinemia: preliminary evidence of activity.
	D319	Catovsky D. et al. <i>Eur J. Cancer</i> 31A(13/14): 2146-54 (1995). Key issues in the treatment of chronic lymphocytic leukaemia (CLL).
	D320	Coiffier B. <i>Ann. Oncol.</i> 83(Suppl 1): S73-S74, 2004. New treatment strategies in lymphomas: aggressive lymphomas.
	D321	Ford et al. <i>Highlights in Oncology Practice</i> 16(2): 40-50, 1998. Immunotherapeutic approaches to treatment of B-cell neoplasms: focus on unconjugated antibodies.
	D322	Kaminski M. et al. <i>Proc. Third Conf. on Radioimmunodetection and Radioimmunotherapy of Cancer</i> , Princeton NJ, 15-17 Nov. 1990 (published at <i>Antibody Immunoconj. Radiopharm.</i> 4: 387, 1991), abst. no. 144. 131-I anti-B1: Initial clinical evaluation in B-cell lymphoma.
↓	D323	Robertson M.J. et al. <i>Blood</i> 79(9): 2229-36, 1992. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia.

EXAMINER <i>A.M. Harris</i>	DATE CONSIDERED <i>28 June 2007</i>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	SHEET 1 OF 1